Skip to main navigation
TCR² Therapeutics
  • Our Science
  • Our Pipeline
  • Patients
    • Clinical Trials
    • Expanded Access Program
  • About Us
  • Investors & Media
    • Overview
    • Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • Analyst Coverage
    • Events
    • SEC Filings
    • FAQs
  • Get in Touch
  • Join Us
  • Home
  • Our Science
  • Our Pipeline
  • Patients
    ►
      ◄ Back
    • Clinical Trials
    • Expanded Access Program
  • About Us
  • Investors & Media
    ►
      ◄ Back
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • FAQs
  • Get in Touch
  • Join Us

Investors & Media

Press Releases

All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Nov 12, 2019

TCR² Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Oct 09, 2019

TCR² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People Officer

Sep 27, 2019

TCR² Therapeutics to Present at the Cantor Global Healthcare Conference

Aug 30, 2019

TCR² Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference

Aug 08, 2019

TCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 06, 2019

TCR² Therapeutics to Participate in Upcoming Conferences in August

Aug 06, 2019

TCR² Therapeutics Deepens Manufacturing and Immuno-Oncology Expertise with Key Hires

Jul 31, 2019

TCR² Therapeutics Announces Partnership with the National Cancer Institute for Phase 1/2 Trial of TC-210

Jun 28, 2019

TCR² Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

May 13, 2019

TCR² Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
  • Contact IR
  • Our Science
  • Our Pipeline
  • Patients
  • About Us
  • Investors & Media
  • Get in Touch
  • Join Us

© 2023 TCR² Therapeutics. All rights reserved.

TCR² Therapeutics